Skip to content

BIOTRICITY INC.: 10-Q filed 2024-11-14

What BIOTRICITY INC. reported in its quarterly report filed 2024-11-14 (fiscal Q2 2025): 43 published measures, 130 facts as tagged in accession 0001493152-24-046028.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-14
Fiscal period
fiscal Q2 2025
Accession
0001493152-24-046028 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOTRICITY INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-305,292,060USD
At 2024-03-315,942,625USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-3034,172,790USD
At 2024-03-3135,919,442USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-31,166,835USD
At 2024-06-30-29,779,690USD
At 2024-03-31-31,465,737USD
At 2023-09-30-26,729,036USD
At 2023-06-30-23,411,614USD
At 2023-03-31-19,845,385USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-30173,270USD
At 2024-03-31786,060USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,561,768USD92
2024-04-01 to 2024-09-30-5,256,288USD183
2023-07-01 to 2023-09-30-3,690,840USD92
2023-04-01 to 2023-09-30-7,103,722USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-1,891,299USD183
2023-04-01 to 2023-09-30-4,222,154USD183

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-07-01 to 2024-09-303,266,846USD92
2024-04-01 to 2024-09-306,468,589USD183
2023-07-01 to 2023-09-302,891,297USD92
2023-04-01 to 2023-09-305,912,062USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-04-01 to 2024-09-301,339,279USD183
2023-04-01 to 2023-09-304,758,634USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-136,101,106USD
At 2024-03-31-127,499,785USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3022,493,626shares92
2024-04-01 to 2024-09-3018,354,277shares183
2023-07-01 to 2023-09-308,795,742shares92
2023-04-01 to 2023-09-308,774,242shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3022,493,626shares92
2024-04-01 to 2024-09-3018,354,277shares183
2023-07-01 to 2023-09-308,795,742shares92
2023-04-01 to 2023-09-308,774,242shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.073USD/shares92
2024-04-01 to 2024-09-30-0.469USD/shares183
2023-07-01 to 2023-09-30-0.441USD/shares92
2023-04-01 to 2023-09-30-0.853USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.073USD/shares92
2024-04-01 to 2024-09-30-0.469USD/shares183
2023-07-01 to 2023-09-30-0.441USD/shares92
2023-04-01 to 2023-09-30-0.853USD/shares183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-3012,576USD
At 2024-03-3115,552USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-04-01 to 2024-09-30115,863USD183
2023-04-01 to 2023-09-30374,515USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-307,672USD92
2024-04-01 to 2024-09-30-1,424,518USD183
2023-07-01 to 2023-09-30-2,185,673USD92
2023-04-01 to 2023-09-30-4,502,159USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-304,064,495USD
At 2024-03-314,470,573USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-07-01 to 2024-09-30752,075USD92
2024-04-01 to 2024-09-301,520,748USD183
2023-07-01 to 2023-09-30753,268USD92
2023-04-01 to 2023-09-301,413,780USD183
2022-11-01 to 2022-11-30364,000USD30

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-3021,489,309USD
At 2024-03-3122,698,826USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-09-301,499,990USD
At 2024-03-311,468,655USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,766,846USD92
2024-04-01 to 2024-09-306,246,860USD183
2023-07-01 to 2023-09-304,184,951USD92
2023-04-01 to 2023-09-308,418,141USD183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-301,817,561USD
At 2024-03-311,879,402USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,459,174USD92
2024-04-01 to 2024-09-304,822,342USD183
2023-07-01 to 2023-09-301,999,278USD92
2023-04-01 to 2023-09-303,915,982USD183

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2024-07-01 to 2024-09-30807,672USD92
2024-04-01 to 2024-09-301,646,247USD183
2023-07-01 to 2023-09-30892,019USD92
2023-04-01 to 2023-09-301,996,080USD183

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,248,864USD92
2024-04-01 to 2024-09-305,214,983USD183
2023-07-01 to 2023-09-303,487,331USD92
2023-04-01 to 2023-09-307,007,546USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-30517,982USD92
2024-04-01 to 2024-09-301,031,877USD183
2023-07-01 to 2023-09-30697,620USD92
2023-04-01 to 2023-09-301,410,595USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3022,863,261shares
At 2024-03-319,353,768shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-30104,842,124USD
At 2024-03-3195,723,083USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-09-30-73,415USD
At 2024-03-3132,378USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-09-301,023,318USD
At 2024-03-311,221,593USD
At 2023-09-301,409,172USD
At 2023-03-311,587,492USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-09-301,167,203USD
At 2024-03-311,386,486USD
At 2023-09-301,531,231USD
At 2023-03-311,722,095USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-09-3029,767USD
At 2024-03-3129,767USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-3017,191USD
At 2024-03-3114,215USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-304,232,727USD
At 2024-03-314,369,576USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,561,768USD92
2024-04-01 to 2024-09-30-5,256,288USD183
2023-07-01 to 2023-09-30-3,690,840USD92
2023-04-01 to 2023-09-30-7,103,722USD183

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,782,405USD92
2024-04-01 to 2024-09-30-8,707,114USD183
2023-07-01 to 2023-09-30-3,600,042USD92
2023-04-01 to 2023-09-30-7,377,451USD183

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,653,029USD92
2024-04-01 to 2024-09-30-8,601,321USD183
2023-07-01 to 2023-09-30-3,881,282USD92
2023-04-01 to 2023-09-30-7,482,861USD183

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-04-01 to 2024-09-302,977USD183
2023-04-01 to 2023-09-302,977USD183

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-07-01 to 2024-09-3036,314USD92
2024-04-01 to 2024-09-30-193,486USD183
2023-07-01 to 2023-09-30-143,380USD92
2023-04-01 to 2023-09-30-129,945USD183

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-04-01 to 2024-09-301,235,256USD183
2023-04-01 to 2023-09-301,046,621USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-04-01 to 2024-09-30125,221USD183
2023-04-01 to 2024-03-31119,285USD366
2023-04-01 to 2023-09-30119,285USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-39,873USD183
2023-04-01 to 2023-09-30411,440USD183

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-61,841USD183
2023-04-01 to 2023-09-30-208,810USD183

Inspect the source

Entity
BIOTRICITY INC. / CIK 0001630113
Captured
2026-09-21T17:22:14.606Z
SEC response SHA-256
de56e3354d4180362d8bf36a6dd02ff7fd0db9690bc31c81e452959deb9a8d37

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001630113.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))